> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Less-Frequent Dosing Schedule for Lilly’s Ebglyss
- URL: https://www.fdaweb.com/fda-oks-less-frequent-dosing-schedule-for-lillys-ebglyss/
- Published: 2026-06-10T12:00:00.000Z
- Updated: 2026-09-14T13:40:53.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161291

FDA has approved an expanded dosing regimen for Lilly’s atopic dermatitis treatment Ebglyss (lebrikizumab-lbkz), allowing certain patients to receive maintenance injections once every eight weeks. Ebglyss was originally approved in the U.S. in 2024 as a first-line biologic treatment administered once every four weeks with or without topical corticosteroids for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well-controlled with topical prescription therapies.

The approval makes Ebglyss the first biologic for moderate-to-severe atopic dermatitis with a maintenance schedule requiring as few as six injections annually without mandatory use of prescription topical therapies, according to Lilly.

The expanded dosing option is based on exposure-response modeling and data from an extension of the Phase 3 ADjoin trial, which evaluated maintenance dosing every four weeks and every eight weeks over a 32-week period. Lilly said the data demonstrated durable disease control with the less-frequent dosing schedule.

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin disease characterized by itching, skin lesions and recurring flares. Patients with moderate-to-severe disease often require long-term treatment to maintain symptom control.

Ebglyss is a monoclonal antibody that selectively targets interleukin-13 (IL-13), a key cytokine involved in the inflammatory pathways underlying atopic dermatitis.